Australia’s experiment with psychedelic medicine has shown promising results for treating post-traumatic stress disorder (PTSD), but the high cost and limited access are significant concerns. Over the past two years, more than half of patients who received MDMA-assisted therapy along with psychotherapy reported significant relief from PTSD symptoms. No serious adverse events were recorded among nearly 200 patients.
However, the treatment’s high cost is limiting access for many Australians suffering from PTSD. The average cost of up to three dosing sessions and 40 hours of counseling is $20,000, making it largely unaffordable for the estimated one million Australians who suffer from the mental health condition.
Only a few dozen psychiatrists are authorized to prescribe MDMA, and most practice in coastal cities, further restricting access. The Therapeutic Goods Administration, Australia’s counterpart to the FDA, has stringent oversight due to MDMA’s experimental status.
Despite these challenges, advocates argue that complex licensing requirements dissuade participation in the program. Mind Medicine Australia, an advocacy group, is pushing regulators to reduce costs and widen access by loosening restrictions on who can dispense the drug and who qualifies for treatment.
Patients who have undergone MDMA therapy report life-changing benefits, including reduced anxiety and depression symptoms. However, the long-term effects of the treatment remain unknown, and experts emphasize the need for more research.
In contrast, psilocybin therapy, available in Oregon and Colorado, has shown different results, with some patients experiencing lasting improvement. Australia’s program is modeled on protocols developed by the Multidisciplinary Association for Psychedelic Studies (MAPS), an American nonprofit that has spent decades developing a therapeutic model for MDMA.
As the treatment gains wider attention from regulators and practitioners, it remains to be seen whether its benefits persist over time.
Source: https://www.nytimes.com/2026/03/24/health/mdma-therapy-ptsd-psychedelic-australia.html